

U O W

Drawing on regional data analytics and stakeholder consultation to improve responses to methamphetamine-related harm in the Illawarra Shoalhaven region

Briony Larance, Peter Kelly, Luise Lago, Laura Robinson, Julia Lappin, Sarah Adams, David Reid



**UNIVERSITY
OF WOLLONGONG
AUSTRALIA**

Acknowledgements



This study is funded by the National Centre for Clinical Research on Emerging Drugs (NCCRED) funded by Commonwealth Department of Health.

Thank you to our collaborating partners.



Overview

PRESENTATION ROAD MAP

Background to the Illawarra Shoalhaven region

Current study aims

Methods

1. Regional data analytics – CHRISP/IHIP data
2. Systematic Review
3. Qualitative Interviews

Conclusions



Background

Methamphetamine use and harms

BACKGROUND

- 3-fold ↑ regular and dependent methamphetamine use since 2009; estimated 268,000 people use regularly, 160,000 dependent¹.
- ↑ more potent crystalline forms of methamphetamine (ice), ↑ in methamphetamine-related harm².
- Helpline calls, drug treatment episodes, arrests and hospital admissions for amphetamine disorders and psychosis all peaked in the mid 2000s, declined for several years, and then steep ↑ since 2010².
- Nationally, estimated to cost Australia around \$5 billion per year³.

References:

1. Degenhardt L, et al. Estimating the number of regular and dependent methamphetamine users in Australia, 2002-2014. *Med J Aust* 2016; 204(4): 153.
2. Degenhardt L, et al. Crystalline methamphetamine use and methamphetamine-related harms in Australia. *Drug and Alcohol Review* 2017; 36(2): 160-70.
3. Tait RJ, et al. Quantifying the societal cost of methamphetamine use to Australia. *International Journal of Drug Policy* 2018; 62: 30-6.



Illawarra Shoalhaven Local Health District

BACKGROUND

- 250km of coastline; more than 400,000 residents; 8 public hospitals¹.
- 7% Nowra-Bomaderry residents identify as ATSI (2.5% NSW and National)².
- High levels of socio-economic disadvantage in the Jervis Bay, Nowra and Wollongong/ Shellharbour regions³.
- Higher unemployment and lower labour participation rates; unemployment in Bomaderry is 10% (vs. NSW 5.2%)⁴.
- 152,000+ presentations to the emergency department in 2017¹.
- ISLHD Stimulant Treatment Program (since 2016) provides community-based counselling, medical review and pharmacotherapy (accepts referrals aged 16 years+).



References:

1. Illawarra Shoalhaven Local Health District. Strategic Directions for Illawarra Shoalhaven Health District: 2017-2020: NSW Health, 2017.
2. ABS. Census of Population and Housing, 2016. Australia: Australian Bureau of Statistics, 2016.
3. ABS. Census of Population and Housing: Socio-economic Indexes for Areas (SEIFA). Australia: Australian Bureau of Statistics, 2016.
4. ABS. Labour Force, Australia, September 2018 (cat. no. 6202.0) Australian Bureau of Statistics, 2018.



Current Study

BACKGROUND

- Existing data capacity in the region presents a unique opportunity to understand methamphetamine care pathways.
- Important for regional planning and service delivery, but also of national and international significance.
- Epidemiological and qualitative data collections, including clinical and consumer consultation.
- Together, these data will inform priorities for intervention and design of a locally-tailored, innovative, integrated model of care.
- Methods:
 1. Regional data analytics - CHRISP/IHIP data
 2. Systematic review
 3. Qualitative interviews



(i) Regional data analytics

Illawarra Health Information Platform (IHIP)

CENTRE FOR HEALTH RESEARCH ILLAWARRA SHOALHAVEN POPULATION (CHRISP)

- Research partnership between UOW and ISLHD (commenced 2016)

Centre for Health Research Illawarra Shoalhaven Population (CHRISP)

- Multidisciplinary team with expertise in research, medicine, public health, pharmacy, epidemiology, statistics, data integration & linkage

Technical platform – Illawarra Health Information Platform (IHIP)

- health records linkage system
- non-identified health databank – ISLHD & other providers
- research datasets owned by ISLHD, managed by CSC




Illawarra Health Information Platform (IHIP)

CONTINUED

- **Core business of the research partnership is to:**
 - Provide access to high quality health data
 - Build capacity for research and development
 - Undertake research
 - **Population health, health services & clinical research**
 - Translate research findings into policy and practice



IHIP Data Sets



	Original – Core
	Added or approvals underway
	Added - Project-specific
	Under Negotiation



IHIP data: Cohort Study



IHIP data: Cohort Study

First methamphetamine-related presentation*




IHIP data: Cohort Study

First methamphetamine-related presentation*

Cohort inclusion criteria:

- ISLHD residents
- Aged 16+ years
- Presenting at acute ISLHD services for MA-related problem



** First methamphetamine-related presentation in ambulance, emergency department and admitted patient data will be identified using ICD-10-AM, ICD-9-CM and SNOMED CT codes for amphetamine/psychostimulant-related disorders, looking across presenting information, additional information, presenting problem, diagnosis_1 - diagnosis_5*




IHIP data: Cohort Study



Cohort inclusion criteria:

- ISLHD residents
- Aged 16+ years
- Presenting at acute ISLHD services for MA-related problem



** First methamphetamine-related presentation in ambulance, emergency department and admitted patient data will be identified using ICD-10-AM, ICD-9-CM and SNOMED CT codes for amphetamine/psychostimulant-related disorders, looking across presenting information, additional information, presenting problem, diagnosis_1 - diagnosis_5*



IHIP data: Cohort Study

12 months “look-back”


First methamphetamine-related presentation*

48 months “follow-up”

Cohort inclusion criteria:

- ISLHD residents
- Aged 16+ years
- Presenting at acute ISLHD services for MA-related problem

** First methamphetamine-related presentation in ambulance, emergency department and admitted patient data will be identified using ICD-10-AM, ICD-9-CM and SNOMED CT codes for amphetamine/psychostimulant-related disorders, looking across presenting information, additional information, presenting problem, diagnosis_1 - diagnosis_5*



Key outcomes:

- Patient characteristic (socio-demographics, comorbidities, other substance use)
- Visit characteristics
- Temporal trends in health service utilisation
- Persistence in HSU
- Patterns of referral
- Linkage with AOD Clinical Liaison services
- Uptake of AOD services



(ii) Systematic review

Systematic Review

CHARACTERISTICS AND EFFECTIVENESS OF BRIEF INTERVENTIONS FOR METHAMPHETAMINE USE IN PRIMARY AND ACUTE HEALTHCARE SETTINGS

1. What are the characteristics of brief interventions for psychostimulant use in primary and acute healthcare settings, and what is their level of specificity regarding (meth)amphetamine use and use disorders?
2. What is the evidence on the efficacy/effectiveness of brief interventions targeting (meth)amphetamine use in non-treatment-seeking populations?



Systematic Review

DEFINITION OF 'BRIEF INTERVENTION'

- Aims to reduce psychostimulant use and/or harm
- Time-limited (1-4 sessions)
- 1+ Screening, Brief Intervention, Referral to Treatment (SBIRT) element,
AND
- 1+ FRAMES element (feedback, responsibility, advice, menu of options,
empathy, self-efficacy)



Systematic Review

METHODS

Primary outcomes:

1. Psychostimulant/
(meth)amphetamine use;
and/or
 2. Psychostimulant/
(meth)amphetamine-related
consequences; and/or
 3. Linkages to psychostimulant/
(meth)amphetamine
treatment
- *Any primary outcomes
related to these domains
will be eligible for inclusion.
No other outcome
measurement will be used
for review inclusion criteria.*

Secondary outcomes:

1. Health service utilisation (e.g.,
GP, ED, ambulance, hospital)
 2. Physical health problems
 3. Mental health symptoms (e.g.,
psychological distress, anxiety,
depression, psychotic
symptoms)
 4. Quality of life
 5. Referrals and referral uptake
- *Data for these secondary
outcomes will be collected
when reported in the
primary studies.*


Other inclusion criteria:

- Peer-reviewed literature
- All intervention study designs
(RCTs, non-RCTs, controlled
before-after studies, case-
control studies, etc)
- English language
- 2000-2019



Systematic Review

SCREENING COMPLETED



(iii) Qualitative interviews

Qualitative interviews

VIEWS OF ISLHD CLINICIANS AND PEOPLE WHO USE METHAMPHETAMINE

CLINICIAN INTERVIEWS (N=15)

Semi-structured interviews with clinicians working in AOD, mental health, inpatient hospital and ED settings.

Key outcomes:

- Local clinical pathways for people experiencing methamphetamine-related harm.
- Effectiveness of existing strategies
- Opportunities for improving models of care
- Barriers to changing practice.

PEOPLE WHO USE METHAMPHETAMINE (N=20)

Semi-structured interviews with people living in ISLHD region who use MA (including both in- and out-of-treatment populations).

Key outcomes:

- Help-seeking strategies and preferences
- Opportunities for improving linkage with harm reduction and treatment services
- Barriers to help-seeking



Summary and conclusions

Research Outcomes

- Describe the demographic and clinical profiles of people who present to ISLHD emergency/acute healthcare services for MA-related problems (including young people).
- Understand the proportion of people referred to specialist AOD services, the proportion who attend AOD services, and predictors of these outcomes.
- Understand coding issues in emergency/acute healthcare settings.
- IHIP data will be used alongside the systematic review and qualitative interviews with ISLHD staff and people who use MA to inform a screening/referral intervention that can be implemented and evaluated.



Capacity-building

- New research partnerships
- Co-led by clinicians and researchers with the aim of generating immediately-translatable evidence to inform practice
- Research capacity-building
- Building research track records and profile
- ISLHD investigators are involved at each stage, including planning, data collection and co-designing future intervention(s)



U



UNIVERSITY
OF WOLLONGONG
AUSTRALIA

O

Thank you

Dr Briony Larance
VC Postdoctoral Senior Research Fellow
School of Psychology
University of Wollongong
☎ +61 2 4239 2243
✉ blarance@uow.edu.au

W